SEC EDGAR CompanyFacts fact · reporting period
Lyell Immunopharma, Inc.: cashflow_financing
One fact, its scope and the complete path back to the official record.
Reported value
$184.000k{"amount": 184000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"}- Entity
- Lyell Immunopharma, Inc.
- Metric
- cashflow_financing
- Period
- 2025-01-01 – 2025-06-30
- Status
- current
- Source
- SEC EDGAR CompanyFacts
Provenance
Source licenseUS-PD-17USC105
Retrieved2026-08-19T18:12:11.294506+02:00
Raw response SHA-256
f7bde1a401b286c74a2fd824ee1df541…Official-identifier path
https://factanker.com/fact/sec/cik-0001806952/cashflow-financing/2025-06-30 (CIK, metric, reporting date)History
- no predecessors — first report
Why this page exists
The UUID above is the stable citation anchor: it never changes, and corrections supersede rather than overwrite. Cite the URL and any reader — human or machine — can verify the value against the official filing.